PharmaGraphX

Log in Get Started

Sorafenib

Nexavar

Tyrosine kinase inhibitor

Standard

Half-life

25-48 hours

Protein Binding

99.5%

Metabolized By

N/A

External

Drugs.com

Clinical alerts

Bleeding risk

Additive with other antithrombotics and NSAIDs

QT prolongation

Avoid combining with other QT-prolonging agents; check electrolytes

Hepatotoxic

Monitor liver function

Mechanism of action

Inhibits RAF, VEGFR, PDGFR, KIT, FLT3, RET

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Acute Myeloid Leukemia
·Acute Myeloid Leukemia Post Cytotoxic Therapy
·Recurrent Adult Acute Myeloid Leukemia
·Secondary Acute Myeloid Leukemia
·Advanced Malignant Solid Neoplasm

Interactions

No curated interaction pairs are recorded for Sorafenib. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Hand-foot syndrome
Diarrhea
Rash
Fatigue
Hypertension

Food, alcohol & herbal

Food

Take on empty stomach (1 hour before or 2 hours after eating)

Alcohol · moderate

Additive hepatotoxicity

Pharmacokinetics

Half-life: 25-48 hours
Protein binding: 99.5%
Metabolised by: CYP3A4

Pregnancy & lactation

Not recorded for Sorafenib. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement